Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lonza to acquire five US manufacturing sites from Merck KGaA
The acquisition involves a total enterprise valuation in the low- to mid-triple-digit millions of Swiss francs. It would expand Lonza’s US manufacturing presence from four to nine sites
The acquisition involves a total enterprise valuation in the low- to mid-triple-digit millions of Swiss francs. It would expand Lonza’s US manufacturing presence from four to nine sites
The deal for the vaccine was awarded through the UK Health Security Agency. Under the contract, the company will deliver scheduled shipments of MVA-BN across the term. The
Caused by HPV-6 and/or HPV-11 primarily, RRP is characterised by the development of wart-like growths in the respiratory tract. The DNA-based immunotherapy, generically known as doruxapapogene ralaplasmid and
This transaction would add Castle Creek’s gene-modified cell therapy candidate D-Fi to Pelthos’s dermatology portfolio. The combined company would operate as Pelthos Therapeutics and continue trading on the
The companies submitted the application seeking accelerated approval in the US. Their decision to withdraw follows discussions with the US Food and Drug Administration (FDA), which indicated that
The medication aims to reduce the volume of heterotopic ossification (HO) in these individuals and is administered orally at a recommended dose of 100mg once daily. Developed by
This decision provides a new therapeutic option for patients who have received at least one previous treatment. Teclistamab is a bispecific antibody administered via subcutaneous injection. It targets
Seralutinib is intended for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The private investment comprises an initial closing, a
These conditions often result in organ failure due to myofibroblast activation, scarring, and tissue inflammation. Ono will work alongside Mediar to utilise its fibrosis-focused discovery platform, expertise in
This collaboration will focus on utilising Evotec’s data-driven discovery platform alongside its AI data science and advanced screening technologies. It aims to accelerate the discovery and validation of